Tag: FDA-approved lymphoma treatments 2025

Home / FDA-approved lymphoma treatments 2025

Categories

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

On February 11, 2025, the Food and Drug Administration authorized the use of brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in conjunction with lenalidomide and a rituximab produc...
fda-approved-lymphoma-treatments-2025

Scan the code